Christopher Scrase

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Christopher M. Nutting, James P. Morden, Kevin J. Harrington et al. · The Lancet Oncology · 2011 · 1.7K citations · Full text

Medicine, Oncology, Radiation Oncology +13

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David P. Dearnaley, Isabel Syndikus, Helen Mossop et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

David P. Dearnaley, Matthew R. Sydes, John D. Graham et al. · The Lancet Oncology · 2007 · 908 citations

Medicine, Oncology, Radiation Oncology +17

COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey et al. · The Lancet Oncology · 2020 · 600 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

David P. Dearnaley, Gordana Jovic, Isabel Syndikus et al. · The Lancet Oncology · 2014 · 462 citations · Full text

Medicine, Oncology, Radiation Oncology +14